Find BPC-157 Peptide Therapy Near You

What Makes a BPC-157 Provider “Verified”?

There are many clinicians willing to prescribe BPC-157 in 2026. Far fewer have the training, sourcing discipline, and monitoring practices that separate safe peptide therapy from reckless peptide therapy. The Peptide Association verification process screens for all four:

Credentials check

Every listed provider holds an active state medical license (MD, DO, NP, or PA) and, where applicable, board certification in a relevant specialty. Licensure is re-verified on an ongoing basis; a lapsed license results in immediate removal from the directory.

Sourcing transparency

Listed providers must name the 503A or 503B compounding pharmacy (or pharmacies) they use for BPC-157 and be willing to explain their sourcing standards to patients. Providers who source from research-chemical suppliers — regardless of label — are not listed.

Clinical experience threshold

BPC-157 is not a compound to prescribe for the first time on a new patient. Listed providers have documented clinical experience prescribing BPC-157 — a minimum case volume that makes them able to recognize patterns, manage adverse events, and individualize protocols.

Ongoing education requirements

Peptide therapy is a moving target: regulatory positioning shifts, new evidence emerges, protocols evolve. Verified providers maintain continuing education in peptide therapy and longevity medicine. The Peptide Association certification program sets the standard many listed providers meet or exceed.

Telemedicine vs. In-Person BPC-157 Care

When telemedicine works

Telemedicine is a good fit for initial consultations that don't require a hands-on exam, for lab reviews, for follow-ups on stable protocols, and for patients in regions with no local peptide-experienced clinicians. BPC-157 is patient-administered via subcutaneous injection after training, so ongoing in-person visits aren't required for most protocols.

When in-person is required

In-person visits are preferred (and in some states, required) when the indication involves a physical exam — an acute injury, suspected structural damage, or a complicated orthopedic history. Some patients also prefer in-person injection training on the first visit before transitioning to self-administration.

State-by-state telemedicine restrictions

State medical boards set the rules for telemedicine prescribing — including whether an initial visit must be in-person, whether out-of-state providers can prescribe, and what documentation is required. The directory's state filter surfaces providers licensed in your state, including those offering telehealth.

What to Expect at Your First Appointment

A well-run first BPC-157 appointment covers four things:

• Comprehensive intake — your indication, medical history, current medications and supplements, allergies, goals, and any previous peptide use.
• Baseline labs — at minimum a CBC, CMP, lipid panel, and indication-specific workup. Some providers run broader hormonal or metabolic panels depending on your history.
• Protocol design and informed consent — dose, frequency, route, expected timeline, monitoring plan, and a clear acknowledgment that BPC-157 is not an FDA-approved finished drug.
• Injection training — reconstitution, site rotation, needle disposal, and what adverse reactions warrant a call back.

Questions to Ask a Potential BPC-157 Provider

If you're choosing between providers, the following questions surface the differences that matter. Any reputable clinician will answer them directly.

Sourcing and safety

1. Which compounding pharmacy fills your BPC-157 prescriptions, and is it 503A or 503B?
2. Have you ever had an adverse batch from that pharmacy, and how did you handle it?
3. How do you confirm potency and purity for the compounds you prescribe?

Protocol and monitoring

1. What baseline labs do you require before starting BPC-157?
2. How do you individualize dosing for my specific indication?
3. What's the planned cycle length, and how do you decide whether to continue?
4. What follow-up lab cadence do you build into the protocol?

Clinical experience

1. How many patients have you treated with BPC-157 specifically?
2. What indications do you most commonly treat?
3. What adverse events have you seen, and how did you manage them?